In the environment described above, continuing review often loses out. Even where there is the will, there often is not the time to go beyond the perfunctory obligations. A lack of feedback from other entities that oversee multi-site trials contributes to the problem. The result is that IRBs have all too little information about how the informed consent process really works and about how well the interests of subjects are being protected during the course of research. That Threaten Their Independence.
Clinical research provides revenue and prestige to the institutions to which many IRBs belong.
The institutions expect IRBs to support these interests at the same time that they protect human subjects. The resulting tension can lessen the IRBs focus on their basic mission. For independent IRBs, the dependence on revenue from industry sponsors exerts similar possibilities for conflict. They Provide Little Training for Investigators and Board Members . The RI3 system depends heavily on research investigators commitment to uphold human-subject protections.